Carebot s.r.o.
5
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 5 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Evaluation of Carebot AI MMG Medical Device for Breast Lesion Detection and Density Assessment
Role: lead
Enhancing Diagnostic Accuracy in Fracture Identification on Musculoskeletal Radiographs Using Deep Learning
Role: lead
Diagnostic Accuracy of Carebot AI MMG in Mammography Screening: Multicenter MRMC Study
Role: lead
Multi-Reader Retrospective Study Examining Carebot AI CXR 2.0.21-v2.01 Implementation in Everyday Radiology Clinical Practice
Role: lead
Retrospective Study of Carebot AI CXR Performance in Preclinical Practice
Role: lead
All 5 trials loaded